Mild side effects of Tremfya include injection site reactions and upper respiratory infections. Though rare, Tremfya can also cause serious side effects, including severe infections. Your doctor may ...

Tremfya is a brand-name drug used to treat moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severely active ulcerative colitis (UC), and Crohn’s disease. Tremfya is given ...

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

How Does Tremfya Work for Crohn's Disease? Tremfya is a type of medicine called a monoclonal antibody. It works by targeting a protein in your body called interleukin-23 (IL-23). IL-23 is a cytokine ...

The FDA has approved Tremfya (guselkumab; Janssen) One-Press, a single-dose patient-controlled injector for the treatment of moderate-to-severe plaque psoriasis in adults. The Food and Drug ...

TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and ...

Tremfya’s more common side effects include upper respiratory infection, headache, injection site reactions, and joint pain. Tremfya may reduce immune system activity and increase the risk of infection ...

MorphoSys Announces that its Licensee Janssen Has Received U.S. FDA Approval for Tremfya(R) One-Press Patient-Controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis (news with ...

Tremfya is used to treat irritable bowel disease (ulcerative colitis and Crohn’s disease) in adults. It’s also approved for plaque psoriasis and psoriatic arthritis in adults and some children.

The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statistically significant rates of endoscopic remission at one year in the pivotal ...

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved a subcutaneous induction regimen of TREMFYA (guselkumab) for the treatment of adults with ...